



## Circulating Tumor Cells: Origin, Fate, and Roles in Immune Evasion and Metastasis

Guest Editors:

**Dr. Luis Del Pozo-Yauner**

Department of Pathology,  
College of Medicine, University of  
South Alabama, Mobile, AL, USA

**Prof. Dr. Ajay Pratap Singh**

1. Department of Pathology,  
College of Medicine, University of  
South Alabama, Mobile, AL  
36604, USA  
2. Cancer Biology Program,  
Mitchell Cancer Institute,  
University of South Alabama,  
Mobile, AL 36604, USA

Deadline for manuscript  
submissions:

**15 December 2024**

### Message from the Guest Editors

The past two decades have witnessed immense progress in the CTCs research, especially in the following areas: 1) The tumor microenvironment factors that drive the dissemination of tumor cells into the circulation; 2) The interaction of CTCs with circulating immunocompetent cells and their evasion of immunosurveillance; 3) The role of CTCs in the resistance to antitumor therapy and facilitation of metastases; and 4) The potential utility of CTCs as tumor markers and therapeutic targets. However, the advent of novel methods for isolating of CTCs and their characterization at the single-cell level in recent years have significantly advanced the understanding of their biology and clinical relevance. Consequently, CTCs have become a topic of interest for a broad spectrum of professionals, from oncologists and pathologists to researchers dedicated to basic, clinical, and translational studies.

Therefore, this Special Issue of *Cancers* invites research articles and timely reviews on all aspects of the biology of CTCs, their roles in cancer progression and metastasis, and the advances in immunotherapy targeting CTCs.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)